Entrada Therapeutics, a privately-held biotechnology company, announced the successful completion of a $116 million Series B financing.

The Series B financing was led by Wellington Management Company. Wellington Management was joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (QIA), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm. Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.


Entrada Therapeutics' mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada's technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol.